Dr. Tarek Hassanein, MD
Claim this profileSouthern California Research Center
Studies Infective Cholangitis
Studies Biliary Cirrhosis
10 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Tarek Hassanein, MD is currently running
Plasma Exchange
for Liver Failure
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the management of subjects with ACLF. Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will consist of a Screening Period during which subjects will be randomized (1:1) to receive either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control group), followed by a Treatment Period, and a Follow-up Period. The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and 17 days, depending on ACLF evolution. The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will receive SMT according to the institution's standards. The Follow-up Period for subjects in both groups will be 90 days.
Recruiting3 awards Phase 3
Volixibat
for Itching in Primary Sclerosing Cholangitis
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Recruiting0 awards Phase 26 criteria
More about Tarek Hassanein, MD
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tarek Hassanein, MD has experience with
- Placebo
- Nivolumab
- Ipilimumab
- Lenvatinib
- Sorafenib
- Albutein 20% Injectable Solution
Breakdown of trials Tarek Hassanein, MD has run
Infective Cholangitis
Biliary Cirrhosis
Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary Sclerosing Cholangitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tarek Hassanein, MD specialize in?
Tarek Hassanein, MD focuses on Infective Cholangitis and Biliary Cirrhosis. In particular, much of their work with Infective Cholangitis has involved treating patients, or patients who are undergoing treatment.
Is Tarek Hassanein, MD currently recruiting for clinical trials?
Yes, Tarek Hassanein, MD is currently recruiting for 2 clinical trials in Coronado California. If you're interested in participating, you should apply.
Are there any treatments that Tarek Hassanein, MD has studied deeply?
Yes, Tarek Hassanein, MD has studied treatments such as Placebo, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Tarek Hassanein, MD?
Apply for one of the trials that Tarek Hassanein, MD is conducting.
What is the office address of Tarek Hassanein, MD?
The office of Tarek Hassanein, MD is located at: Southern California Research Center, Coronado, California 92118 United States. This is the address for their practice at the Southern California Research Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.